Nomura Holdings Inc. Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

Nomura Holdings Inc. acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,924 shares of the biotechnology company's stock, valued at approximately $2,090,000.

Several other institutional investors also recently made changes to their positions in the stock. Mubadala Investment Co PJSC purchased a new stake in shares of United Therapeutics during the 4th quarter valued at $2,386,000. NDVR Inc. increased its holdings in United Therapeutics by 11.4% in the 4th quarter. NDVR Inc. now owns 644 shares of the biotechnology company's stock valued at $227,000 after purchasing an additional 66 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in United Therapeutics by 26.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,446 shares of the biotechnology company's stock valued at $2,281,000 after purchasing an additional 1,342 shares in the last quarter. Investment Management Corp of Ontario increased its holdings in United Therapeutics by 157.2% in the 4th quarter. Investment Management Corp of Ontario now owns 29,904 shares of the biotechnology company's stock valued at $10,551,000 after purchasing an additional 18,278 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in United Therapeutics by 1.9% in the 4th quarter. Janus Henderson Group PLC now owns 468,996 shares of the biotechnology company's stock valued at $165,490,000 after purchasing an additional 8,577 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

UTHR has been the subject of several recent research reports. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Morgan Stanley boosted their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. Finally, HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $392.00.

Insider Activity

In related news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $956,195.85. This trade represents a 79.51% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,500 shares of company stock worth $20,765,280. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $305.35 on Friday. The firm has a market cap of $13.77 billion, a PE ratio of 13.41, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. The firm's 50-day simple moving average is $299.95 and its 200-day simple moving average is $340.58. United Therapeutics Co. has a 1 year low of $264.33 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $6.17 EPS. On average, equities analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.